Managed Healthcare Executive

Analysis reinforces benefit and safety of adjuvant Keytruda for stage 2 melanoma

A secondary analysis of the phase 3 KEYNOTE-716 trial finds that adjuvant Keytruda improves recurrence-free survival without increasing the risk of new primary melanoma and may reduce non-melanoma ...
Thorax

Increase in second primary lung cancers in a nation-wide cohort study from Sweden

Background We describe the occurrence of second primary lung cancers (SPLCs) and their determinant in Sweden. Methods Nation-wide cancer registry from years 1961 to 2021 identified a total of 853 ...

Beverley Callard, 68, says she broke down in tears and refused to let her husband Jon McEwan in the room after her dressings were removed following breast cancer surg…

The Coronation Street actress, 68, revealed she 'cried like a baby' after her dressings were removed for the first time on ...

TARA-002 Demonstrates 68% Complete Response Rate at Six Months in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

The interim analysis of the BCG-Unresponsive cohort includes 35 evaluable participants, of whom, 22 were evaluable at six months and 15 were evaluable at 12 months as of a January 28, 2026 data cutoff ...

ImmunityBio Reports 700% Year-Over-Year Revenue Growth, Expanded ANKTIVA® Approvals in Lung Cancer and Global Commercial Partnerships in 33 Countries with Label Expansion ...

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced full-year 2025 financial and operational highlights, including approximately $113 million in net product ...

Corrie legend Beverley Callard, 68, gives emotional health update as she reveals she was kept in hospital overnight due to 'complications' following her breast cancer surgery

Beverley Callard has revealed that she was kept in hospital overnight due to 'complications' in an emotional post shared to Instagram on Saturday following her breast cancer surgery.
PharmiWeb

ImmunityBio Partners with Biopharma and Cigalah Healthcare to Launch ANKTIVA® in Saudi Arabia for Bladder and Lung Cancer Patients

Biopharma & Cigalah are two of the largest pharmaceutical commercial distributors in the Middle East and North Africa (MENA)ImmunityBio established a wholly owned subsidiary in the Kingdom of Saudi ...

ImmunityBio Expands Access to ANKTIVA(R) in EU with New Distribution Partnership and Opens Irish Subsidiary to Support European Launch

ImmunityBio partner Accord Healthcare to deploy an 85-person sales force to drive ANKTIVA commercialization across 30 countries -- Dublin-based subsidiary to support ImmunityBio's distribution and ...
PharmiWeb

ImmunityBio Receives Authorization from the European Commission for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ, Expanding Global Access to 33 ...

ANKTIVA plus BCG, with a 71% complete response rate, is the first immunotherapy to receive marketing authorization in Europe for non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) ...
Hosted on MSN

Woman says she felt 'pretty good' after surgery to remove cancerous mole on her face — until she took bandage off (exclusive)

Daniela Mullins first noticed the small mole on her face in 2015, but hadn't realized how much it had changed over the years Daniela Mullins went in for a full-body scan while she and her ...
AOL

Woman Says She Felt ‘Pretty Good’ After Surgery to Remove Cancerous Mole on Her Face — Until She Took Bandage Off (Exclusive)

Daniela Mullins went in for a full-body scan while she and her dermatologist were figuring out her postpartum skin When her dermatologist saw the mole on her face, they decided to get a closer look ...